finding,pubmed_id,finding_id
The case report describes a patient with chronic myeloid leukemia who developed interstitial pneumonitis after taking imatinib for two months.,PMC3884114,PMC3884114_0
"The incidence of severe respiratory adverse events due to imatinib is very rare, with interstitial pneumonitis occurring in 0.2% to 1.3% of patients.",PMC3884114,PMC3884114_1
"The patient's symptoms improved with temporarily stopping imatinib and starting steroid therapy, and there was no recurrence of the pneumonitis at a 3-month follow-up after imatinib rechallenge.",PMC3884114,PMC3884114_2
"The diagnosis of imatinib-induced interstitial pneumonitis is based on history, clinical symptoms, radiological findings, and pathological results, which showed fibrous plugs in the alveoli with infiltration of inflammatory cells in the interstitium.",PMC3884114,PMC3884114_3
"The standard treatment for imatinib-induced interstitial pneumonitis is to stop the drug, observe the course of the disease, and optionally administer steroids. Some patients may relapse after readministration of imatinib, and symptoms and chest radiographs should be monitored.",PMC3884114,PMC3884114_4
